Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model
- 27 January 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 224 (6), 1039-1047
- https://doi.org/10.1093/infdis/jiab043
Abstract
The treatment success rate of drug-resistant tuberculosis (DR-TB) is alarmingly low. Therefore, more effective and less complex regimens are urgently required. We compared the efficacy of an all oral DR-TB drug regimen consisting of bedaquiline (25 mg/kg), delamanid (2.5 mg/kg) and linezolid (100 mg/kg) (BDL) on the mycobacterial load in the lungs and spleen of TB infected mice during a treatment period of 24 weeks. This treatment was compared to the standard regimen of isoniazid, rifampicin, pyrazinamide and ethambutol (HRZE). Relapse was assessed 12 weeks post-treatment. Two logistic regression models were developed to compare the efficacy of both regimens. Culture negativity in the lungs was achieved at 8 and 20 weeks of treatment with BDL and HRZE, respectively. After 14 weeks of treatment only one mouse relapsed in the BDL group, while in the HRZE group relapse was still observed at 24 weeks of treatment. Predictions from the final mathematical models showed that a 95% cure rate was reached after 20.5 and 28.5 weeks of treatment with BDL and HRZE, respectively. The BDL regimen was observed to be more effective than HRZE and could be a valuable option for the treatment of DR-TB.Keywords
Funding Information
- Innovative Medicines Initiative Joint Undertaking (115337)
- European Union’s Seventh Framework Programme (FP7/2007–2013)
- European Federation of Pharmaceutical Industries and Associations
- NIH
This publication has 32 references indexed in Scilit:
- Consequences of Noncompliance for Therapy Efficacy and Emergence of Resistance in Murine Tuberculosis Caused by the Beijing Genotype of Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2012
- Pharmacokinetics and Pharmacodynamics of TMC207 and Its N -Desmethyl Metabolite in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2012
- Bactericidal Potencies of New Regimens Are Not Predictive of Their Sterilizing Potencies in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2010
- Effects of Four Different Meal Types on the Population Pharmacokinetics of Single-Dose Rifapentine in Healthy Male VolunteersAntimicrobial Agents and Chemotherapy, 2010
- Population Pharmacokinetics of Linezolid in Adults with Pulmonary TuberculosisAntimicrobial Agents and Chemotherapy, 2009
- Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine ModelAntimicrobial Agents and Chemotherapy, 2009
- Sex Differences in Pharmacokinetics and PharmacodynamicsClinical Pharmacokinetics, 2009
- Early and Extended Early Bactericidal Activity of Linezolid in Pulmonary TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary TuberculosisAntimicrobial Agents and Chemotherapy, 2008
- OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In MicePLoS Medicine, 2006